#1 Clinical Trials Search in Europe

Cilazapril

This article discusses the use of Cilazapril, an ACE inhibitor, in clinical trials for the treatment of IgA nephropathy (IgAN). IgAN is the most common type of primary glomerulonephritis worldwide. The study aims to compare the effectiveness of ACE inhibitors or Angiotensin Receptor Blockers (ARBs) alone versus their combination with steroids in treating IgAN patients. This research is significant as it seeks to determine whether the combined therapy can provide additional benefits while considering potential side effects.

Table of Contents

What is CILAZAPRIL?

CILAZAPRIL, also known by its brand name Inhibace, is a medication that belongs to a class of drugs called ACE inhibitors (Angiotensin-Converting Enzyme inhibitors)[1]. ACE inhibitors work by relaxing blood vessels, which helps to lower blood pressure and improve blood flow throughout the body. This medication is primarily used to treat various cardiovascular and kidney-related conditions.

Medical Conditions Treated with CILAZAPRIL

CILAZAPRIL is used to treat several medical conditions, including:

  • Hypertension (high blood pressure): CILAZAPRIL helps to lower blood pressure by relaxing blood vessels.
  • IgA Nephropathy: This is a kidney disorder where the antibody Immunoglobulin A (IgA) builds up in the kidneys, potentially leading to kidney damage. CILAZAPRIL may be used as part of the treatment for this condition[1].
  • Other cardiovascular conditions: While not specifically mentioned in the provided clinical trial data, ACE inhibitors like CILAZAPRIL are often used to treat heart failure and to protect the heart after a heart attack.

CILAZAPRIL in Combination Therapy

In some cases, CILAZAPRIL may be used in combination with other medications to enhance its effectiveness. The clinical trial data mentions a combination therapy of ACE inhibitors (like CILAZAPRIL) or ARBs (Angiotensin Receptor Blockers) with steroids for treating IgA Nephropathy[1]. This combination therapy is being studied to determine if it provides additional benefits compared to using ACE inhibitors or ARBs alone.

Clinical Trials and Research

A randomized controlled trial (RCT) was conducted to investigate the effectiveness of combining ACE inhibitors/ARBs with steroids in treating primary IgA Nephropathy[1]. The study aimed to compare the efficacy and safety of using ACE inhibitors/ARBs alone versus using them in combination with steroids. This research is important because it helps determine the best treatment approach for patients with IgA Nephropathy.

Effectiveness of CILAZAPRIL

The effectiveness of CILAZAPRIL, particularly in combination with other treatments, is being studied in clinical trials. The research focuses on two primary outcomes:

  1. Serum creatinine levels: This is a measure of kidney function. By monitoring serum creatinine, researchers can assess how well the treatment is protecting the kidneys[1].
  2. 24-hour urinary protein excretion: This measures the amount of protein in the urine over a 24-hour period. Reduced protein in the urine can indicate improved kidney function[1].

These measurements help researchers determine how effective CILAZAPRIL and its combination therapies are in treating IgA Nephropathy and protecting kidney function.

Potential Side Effects

While the provided clinical trial data doesn’t specifically mention side effects of CILAZAPRIL, it’s important to note that all medications can have potential side effects. The trial data mentions that the use of steroids in combination therapy was restricted due to side effects[1]. Common side effects of ACE inhibitors like CILAZAPRIL may include dizziness, headache, and dry cough. However, it’s crucial to consult with your healthcare provider for a complete list of potential side effects and to report any unusual symptoms you may experience while taking this medication.

Aspect Details
Study Type Randomized Controlled Trial (RCT)
Condition Studied IgA Nephropathy (IgAN)
Treatments Compared ACEi/ARB alone vs ACEi/ARB plus steroids
Primary Outcomes Measured Serum creatinine, 24-hour urinary protein excretion
Drugs Used Cilazapril (Inhibace), Losartan (Cozaar), Prednisone
Study Objective Investigate efficacy and safety of combined therapy vs ACEi/ARB alone

FAQ

  • What is IgA nephropathy (IgAN)? IgA nephropathy is the most common type of primary glomerulonephritis, a kidney disease that affects the glomeruli (tiny filters in the kidneys). In IgAN, antibodies called IgA build up in the kidneys, causing inflammation and damage to kidney function over time.
  • What treatments are being compared in this clinical trial? The trial compares two treatment approaches: ACE inhibitors or ARBs (such as Cilazapril) alone versus a combination of ACE inhibitors/ARBs plus steroids in treating IgA nephropathy.
  • Why is this clinical trial important? This trial is important because it aims to determine whether adding steroids to ACE inhibitors/ARBs can provide additional benefits for IgAN patients compared to using ACE inhibitors/ARBs alone. This could potentially lead to more effective treatment strategies for IgA nephropathy.
  • What are the primary outcomes measured in this study? The primary outcomes measured in this study are serum creatinine levels and 24-hour urinary protein excretion. These measurements help assess kidney function and the effectiveness of the treatments being studied.
  • Are there any concerns about using steroids in this treatment? Yes, the use of steroids has been restricted in some cases due to their potential side effects. This trial aims to investigate whether the benefits of combining steroids with ACE inhibitors/ARBs outweigh the potential risks for IgAN patients.

Ongoing Clinical Trials on Cilazapril

  • Study on Preventing Heart Disease in Diabetes Patients Using Eprosartan Mesilate and Drug Combination

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Austria Spain

  • Study of XXB750 and Drug Combination for Patients with Heart Failure

    Not recruiting

    1 1
    Investigated drugs:
    Bulgaria Czechia Denmark France Germany Hungary +5

Glossary

  • IgA nephropathy (IgAN): The most common type of primary glomerulonephritis, a kidney disease where IgA antibodies build up in the kidneys, causing inflammation and damage to kidney function over time.
  • ACEi (ACE inhibitor): A type of medication that helps relax blood vessels by blocking a hormone called angiotensin-converting enzyme. Cilazapril is an example of an ACE inhibitor used in this study.
  • ARB (Angiotensin Receptor Blocker): A type of medication that helps relax blood vessels by blocking the action of a hormone called angiotensin II. Cozaar (losartan) is an example of an ARB used in this study.
  • Glomerulonephritis: Inflammation of the glomeruli, which are tiny filters in the kidneys that help remove waste and excess fluids from the blood.
  • Randomized Controlled Trial (RCT): A type of scientific study where participants are randomly assigned to different treatment groups to compare the effectiveness of different interventions.
  • Serum creatinine: A waste product in the blood that is used as an indicator of kidney function. Higher levels may indicate reduced kidney function.
  • 24-hour urinary protein excretion: A measure of the amount of protein excreted in urine over a 24-hour period, which can indicate kidney damage or disease when elevated.
  • Etiology: The cause or origin of a disease or condition.
  • Multicenter study: A research study conducted at multiple medical centers or institutions to increase the number of participants and improve the generalizability of results.

References

  1. https://clinicaltrials.gov/study/NCT00378443